BioMarin Pharmaceutical announced it will acquire Amicus Therapeutics for $4.8 billion, enhancing its rare disease drug portfolio. The acquisition adds two key drugs, Galafold and Pombiliti + Opfolda, which treat Fabry disease and Pompe disease, respectively. Amicus’ stock jumped more than 30% to nearly match the takeover price of $14.50 per share. BioMarin expects the deal to immediately accelerate its sales and boost earnings, while also securing rights to the potential treatment for kidney disease, DMX-200. 

Duke Energy experienced power outages affecting 305 customers across North Carolina today, underscoring the ongoing challenges the utility faces in maintaining a reliable power grid. In response, Duke Energy is ramping up its investments in grid reliability, proposing significant increases in spending to enhance infrastructure and safeguard against extreme weather conditions. These investments aim to support the growing energy demands in the region, as the utility prepares for future challenges posed by both climate change and population growth.